ESC 365 - Positive hemodynamic effects of CXL-1427, a novel nitroxyl prodrug in advanced heart failure patients.

HFA Premium Access

Positive hemodynamic effects of CXL-1427, a novel nitroxyl prodrug in advanced heart failure patients.

Session: Late Breaking Trials I: Focus on acute heart failure

Topic: Acute Heart Failure

Speaker: Professor V. Mitrovic (Nauheim, DE)

Event: HEART FAILURE 2016

Congress Presentation

Add to my library

About the speaker

Professor Veselin Mitrovic

Kerckhoff-Clinic, Nauheim (Germany)

5 presentations

0 follower

12 more presentations in this session

Bi treatment with hydralazine/nitrates versus placebo in africans admitted with acute heart failure (BA-HEF).

Speaker: Professor K. Sliwa (Cape Town, ZA)

Discussion: BA-HEF.

RELAX-REPEAT: a multicentre, prospective, randomised, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure.

Speaker: Professor J. Teerlink (San Francisco, US)

Discussion: RELAX-REPEAT.

Discussion: CXL-1427.

Access the full session

Late Breaking Trials I: Focus on acute heart failure

Speakers: Professor V. Mitrovic, Professor K. Sliwa, Professor J. Teerlink

About the event

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources